

Electronic Supplementary Information

**Organocatalysts Wrapped Around by Polyethylene Glycols (PEGs): A Unique Host-Guest System for
Asymmetric Michael Addition Reactions**

Dan Qian Xu, Shu Ping Luo, Yi Feng Wang, Ai Bao Xia,

Hua Dong Yue, Li Ping Wang, Zhen Yuan Xu*


*State Key Laboratory Breeding Base of Green Chemistry-Synthesis Technology,
Zhejiang University of Technology, Hangzhou 310014, china*

Table of Contents	Page
1. General Remarks	S-2
2. General Procedure for the Preparation of Pyrrolidinyl-Thioimidazolium Salts 1-3	S-2
3. Typical Experimental Procedure for the Asymmetric Michael Addition Reaction	S-6
4. NMR, ESI-MS and HRMS Spectra of Pyrrolidinyl-Thioimidazolium Salts 1-3	S-9
5. X-Ray Crystal Data and Structure of 1f's Hydrobromide Salt	S-54
6. HPLC Chart for ee Value Determination and Crystal Structure of Michael Adduct 6	S-55
7. References	S-56

1. General Remarks

All starting chemicals were commercial products (Aldrich or J&K Chemica) with analytical grade. Organic solvents were dried and purified before use by usual methods.¹ (*S*)-2-Bromomethyl-pyrrolidine hydrobromide was synthesized according to literatures.² ¹H NMR and ¹³C NMR spectra were recorded on a Varian NMR. Chemical shifts of ¹H and ¹³C were given in δ relative to tetramethylsilane (TMS). Coupling constants *J* were given in Hz. IR spectra were obtained on a Bruker EQUINOX 55. Electrospray ionization (ESI) mass experiments were performed on a Finnigan LCQ Advantage. ESI-HRMS spectra were obtained on a Bruker APEX III FTICR mass spectrometer. GC-MS experiments were performed on an Agilent 6890N GC system with a 5973N mass selective detector. HPLC experiments were carried out using a JASCO LC-2000 Plus system consisting of MD and CD detectors.

2. General Procedure for the Preparation of Pyrrolidinyl-Thioimidazolium Salts 1-3



A mixture of 1-alkyl-2-mercaptoimidazole (10 mmol) and (*S*)-(+)-2-bromomethyl-pyrrolidine hydrobromide (10 mmol) in EtOH (30 mL) was heated with stirring at 80 °C for 8h. After completion, the solvent was removed by distillation and, the residue was recrystallized in EtOH and neutralized by NaOH (10 mmol) to afford the chiral pyrrolidinyl-thioimidazolium salts **1-3**.

The mixture of the chiral pyrrolidinyl-thioimidazolium salt **1** (or **1a**) (5 mmol), potassium salts of the corresponding acids (5 mmol), and EtOH (20 mL) was stirred for 24 h at room temperature. Then, the formed inorganic salt KBr was filtered off, the remained solution was evaporated under vacuum to afford the desired chiral pyrrolidinyl-thioimidazolium salts **1b-1i**.

3-Methyl-2-[(2*S*)-(pyrrolidinyl) methylthio]-3*H*-imidazol-1-ium bromide (**1** or **1a**)

¹H NMR (DMSO-*d*₆, δ ppm) : 1.68-1.77 (m, 1H), 1.83-1.98 (m, 2H), 2.07-2.16 (m, 1H), 3.19-3.22 (m, 2H), 3.35-3.42 (m, 2H), 3.61 (s, 3H), 3.81-3.84 (m, 1H), 7.01 (d, *J*= 1.6 Hz, 1H), 7.33 (d, *J*= 1.6 Hz, 1H), 9.36 (dr, 2H).

¹³C NMR (DMSO-*d*₆, δ ppm): 23.363, 29.217, 33.153, 34.427, 44.581, 59.080, 123.635, 127.919, 139.718.

IR (film, cm⁻¹): 3418 [ν(N-H)], 3107 [ν(C-H) aromatic], 2953 and 2748 [ν(C-H) aliphatic], 1631 [ν(C=C)], 1461 [δ(C-H)], 1412 [δ(S-CH₂)].

ESI-MS: *m/z* 198 [M-Br]⁺, 79 and 81 [Br]⁻.

HRMS: (ESI+) *m/z* calcd for [C₉H₁₆N₃S]⁺198.1059, found 198.1056.

3-Methyl-2-[(2*S*)-(pyrrolidinyl) methylthio]-3*H*-imidazol-1-ium tetrafluoroborate (**1b**)

¹H NMR (DMSO-*d*₆, δ ppm) : 1.67-1.74 (m, 1H), 1.83-2.01 (m, 2H), 2.08-2.15 (m, 1H), 3.19-3.22 (m, 2H), 3.31 (dd, *J* = 8.0, 14.4 Hz, 1H), 3.41 (dd, *J* = 5.6, 14.4 Hz, 1H), 3.67 (s, 3H), 3.72-3.74 (m, 1H), 7.25 (s, 1H), 7.48 (s, 1H), 9.10 (dr, 2H).

¹³C NMR (DMSO-*d*₆, δ ppm): 23.712, 29.468, 34.048, 35.170, 45.271, 59.444, 124.598, 126.038, 139.749.

IR (film, cm⁻¹): 3572 [ν(N-H)], 3149 [ν(C-H) aromatic], 2962 and 2745 [ν(C-H) aliphatic], 1621 [ν(C=C)], 1465 [δ(C-H)], 1413 [δ(S-CH₂)], 1062 [γ (BF)].

ESI-MS: *m/z* 198 [M-BF₄]⁺, 87[BF₄]⁻.

HRMS: (ESI+) *m/z* calcd for [C₉H₁₆N₃S]⁺ 198.1059, found 198.1056. (ESI-) *m/z* calcd for [C₉H₁₆N₃SB₂F₈]⁻ 372.1130, found 372.1115.

3-Methyl-2-[(2*S*)-(pyrrolidinyl) methylthio]-3*H*-imidazol-1-ium hexafluorophosphate (**1c**)

¹H NMR (DMSO-*d*₆, δ ppm) : 1.68-1.77 (m, 1H), 1.83-1.99 (m, 2H), 2.07-2.15 (m, 1H), 3.19 (t, *J* = 7.2 Hz, 2H), 3.28 (dd, *J* = 7.6, 14 Hz, 1H), 3.80 (dd, *J* = 5.2, 14 Hz, 1H), 3.59 (s, 3H), 3.79-3.86 (m, 1H), 6.99 (s, 1H), 7.30 (s, 1H), 9.21 (dr, 2H).

¹³C NMR (DMSO-*d*₆, δ ppm): 23.674, 29.354, 33.252, 34.768, 45.112, 59.610, 123.870 128.245, 140.242.

IR (film, cm⁻¹): 3418 [ν(N-H)], 3157 [ν(C-H) aromatic], 2958 and 2928 [ν(C-H) aliphatic], 1630 [ν(C=C)], 1467 [δ(C-H)], 1414 [δ(S-CH₂)], 835 [γ (PF)].

ESI-MS: *m/z* 198 [M-PF₆]⁺, 145 [PF₆]⁻.

HRMS: (ESI+) *m/z* calcd for [C₉H₁₆N₃S]⁺ 198.1059, found 198.1056. (ESI-) *m/z* calcd for [PF₆]⁻ 144.9636, found 144.9641.

3-Methyl-2-[(2*S*)-(pyrrolidinyl) methylthio]-3*H*-imidazol-1-ium trifluoroacetate (**1d**)

¹H NMR (DMSO-*d*₆, δ ppm) : 1.69-1.76 (m, 1H), 1.83-1.98 (m, 2H), 2.08-2.14 (m, 1H), 3.21 (t, *J* = 6.8 Hz, 2H), 3.31-3.46 (m, 2H), 3.64 (s, 3H), 3.76-3.81 (m, 1H), 7.10 (s, 1H), 7.39 (s, 1H), 9.46 (dr, 2H).

¹³C NMR (DMSO-*d*₆, δ ppm): 23.575, 29.475, 33.562, 34.715, 44.717, 59.118, 124.082, 127.206, 139.650, 158.942.

IR (film, cm⁻¹): 3440 [ν(N-H)], 3144 [ν(C-H) aromatic], 2973 and 2779 [ν(C-H) aliphatic], 1694 [ν(C=O)], 1465 [δ(C-H)], 1416 [δ(S-CH₂)], 1204 [γ (C-F)].

ESI-MS: *m/z* 198 [M-CF₃COO]⁺, 113[CF₃COO]⁻.

HRMS: (ESI+) *m/z* calcd for [C₉H₁₆N₃S]⁺ 198.1059, found 198.1056. (ESI-) *m/z* calcd for [C₂O₂F₃]⁻ 112.9845, found 112.9851.

3-Methyl-2-[(2*S*)-(pyrrolidinyl) methylthio]-3*H*-imidazol-1-ium trifluoromethanesulfonamide (**1e**)

¹H NMR (DMSO-*d*₆, δ ppm) : 1.68-1.77 (m, 1H), 1.83-1.98 (m, 2H), 2.08-2.16 (m, 1H), 3.20 (t, *J* = 7.2 Hz, 2H), 3.29-3.47 (m, 2H), 3.61 (s, 3H), 3.78-3.84 (m, 1H), 7.02 (d, *J* = 1.2 Hz, 1H), 7.33 (d, *J* = 1.2 Hz, 1H), 9.29 (dr, 2H).

^{13}C NMR (DMSO- d_6 , δ ppm): 23.598, 29.392, 33.312, 34.654, 44.846, 59.345, 118.008, 121.208, 123.824, 128.086, 140.007.

IR (film, cm^{-1}): 3572 [$\nu(\text{N-H})$], 3207 [$\nu(\text{C-H})$ aromatic], 2957 and 2752 [$\nu(\text{C-H})$ aliphatic], 1465 [$\delta(\text{C-H})$], 1412 [$\delta(\text{S-CH}_2)$], 1414 [$\delta(\text{S-CH}_2)$], 1351 and 1137 [$\nu(\text{S=O})$], 1189 [$\gamma(\text{C-F})$].

ESI-MS: m/z 198 [$\text{M}-(\text{CF}_3\text{SO}_2)_2\text{N}^+$], 280 [$(\text{CF}_3\text{SO}_2)_2\text{N}^-$].

HRMS: (ESI+) m/z calcd for $[\text{C}_9\text{H}_{16}\text{N}_3\text{S}]^+$ 198.1059, found 198.1056. (ESI-) m/z calcd for $[\text{C}_2\text{F}_6\text{NO}_4\text{S}_2]^-$ 279.9167, found 279.9177.

3-Methyl-2-[(2*S*)-(pyrrolidinyl) methylthio]-3*H*-imidazol-1-ium toluene-4-sulfonate (**1f**)

^1H NMR (DMSO- d_6 , δ ppm) : 1.68-1.1.73 (m, 1H), 1.92-2.06 (m, 2H), 2.20-2.25 (m, 1H), 2.34 (s, 3H), 3.24-3.33 (m, 2H), 3.52-3.57 (m, 1H), 3.64-3.73 (m, 2H), 3.90 (s, 3H), 7.15 (d, $J=8$ Hz, 2H), 7.60 (d, $J=8$ Hz, 2H), 7.66 (s, 1H), 7.80 (s, 1H), 9.27 (dr, 2H).

^{13}C NMR (DMSO- d_6 , δ ppm): 20.883, 23.886, 29.528, 33.570, 35.890, 45.756, 59.072, 124.317, 125.561, 128.344, 128.677, 138.285, 139.673, 144.973.

IR (film, cm^{-1}): 3458 [$\nu(\text{N-H})$], 3112 [$\nu(\text{C-H})$ aromatic], 2971 and 2784 [$\nu(\text{C-H})$ aliphatic], 1624 [$\nu(\text{C=C})$], 1461 [$\delta(\text{C-H})$], 1413 [$\delta(\text{S-CH}_2)$], 1175 and 1010 [$\nu(\text{S=O})$].

ESI-MS: m/z 198 [$\text{M}-p\text{-CH}_3\text{C}_6\text{H}_4\text{SO}_3^+$], 171 [$p\text{-CH}_3\text{C}_6\text{H}_4\text{SO}_3^-$].

HRMS: (ESI+) m/z calcd for $[\text{C}_9\text{H}_{16}\text{N}_3\text{S}]^+$ 198.1059, found 198.1056. (ESI-) m/z calcd for $[\text{C}_7\text{H}_7\text{O}_3\text{S}]^-$ 171.0110, found 171.0111.

3-Methyl-2-[(2*S*)-(pyrrolidinyl) methylthio]-3*H*-imidazol-1-ium β -naphthalenesulfonate (**1g**)

^1H NMR (DMSO- d_6 , δ ppm) : 1.60-1.65 (m, 1H), 1.78-1.88 (m, 2H), 2.01-2.04 (m, 1H), 3.07-3.11 (m, 2H), 3.18-3.30 (m, 2H), 3.58 (s, 3H), 3.65-3.68 (m, 1H), 6.96 (s, 1H), 7.28 (s, 1H), 7.51-7.54 (m, 2H), 7.71 (dd, $J=2, 8.8$ Hz, 1H), 7.86 (d, $J=8.8$ Hz, 1H), 7.89-7.92 (m, 1H), 7.96-7.98 (m, 1H), 8.15 (s, 1H).

^{13}C NMR (DMSO- d_6 , δ ppm): 23.401, 29.422, 35.193, 35.360, 45.081, 58.875, 123.718, 124.256, 125.576, 126.592, 126.820, 127.585, 127.707, 128.571, 132.128, 132.924, 138.543, 144.708.

IR (film, cm^{-1}): 3450 [$\nu(\text{N-H})$], 3109 [$\nu(\text{C-H})$ aromatic], 2968 and 2780 [$\nu(\text{C-H})$ aliphatic], 1631 [$\nu(\text{C=C})$], 1461 [$\delta(\text{C-H})$], 1413 [$\delta(\text{S-CH}_2)$], 1185 and 1030 [$\nu(\text{S=O})$].

ESI-MS: m/z 198 [$\text{M}-\text{C}_{10}\text{H}_7\text{SO}_3^+$], 207 [$\text{C}_{10}\text{H}_7\text{SO}_3^-$].

HRMS: (ESI+) m/z calcd for $[\text{C}_9\text{H}_{16}\text{N}_3\text{S}]^+$ 198.1059, found 198.1056. (ESI-) m/z calcd for $[\text{C}_{10}\text{H}_7\text{O}_3\text{S}]^-$ 207.0110, found 207.0109.

3-Methyl-2-[(2*S*)-(pyrrolidinyl) methylthio]-3*H*-imidazol-1-ium benzoate (**1h**)

^1H NMR (DMSO- d_6 , δ ppm) : 1.68-1.77 (m, 1H), 1.84-2.00 (m, 2H), 2.08-2.16 (m, 1H), 3.21 (t, $J=7.2$, Hz, 2H), 3.31-3.43 (m, 2H), 3.61 (s, 3H), 3.79-3.86 (m, 1H), 7.01 (d, $J=1.6$ Hz, 1H), 7.33 (d, $J=1.6$ Hz, 1H), 7.49-53 (m, 2H), 7.61-7.65 (m, 1H), 7.95 (m, 2H), 9.34 (dr, 2H).

^{13}C NMR (DMSO- d_6 , δ ppm): 23.575, 29.407, 33.411, 34.662, 44.732, 59.239, 123.847, 127.836, 128.624, 129.322, 130.816, 132.909, 139.862, 167.450.

IR (film, cm^{-1}): 3392 [$\nu(\text{N-H})$], 3107 [$\nu(\text{C-H})$ aromatic], 2966 and 2755 [$\nu(\text{C-H})$ aliphatic], 1597 [$\nu(\text{C=C})$], 1548 [$\nu(\text{C=O})$], 1460 and 1378 [$\delta(\text{C-H})$], 1412 [$\delta(\text{S-CH}_2)$].

ESI-MS: m/z 198 [$\text{M-C}_6\text{H}_5\text{COO}]^+$, 121 [$\text{C}_6\text{H}_5\text{COO}]^-$.

HRMS: (ESI+) m/z calcd for [$\text{C}_9\text{H}_{16}\text{N}_3\text{S}]^+$ 198.1059, found 198.1056. (ESI-) m/z calcd for [$\text{C}_7\text{H}_5\text{O}_2$] 121.0284, found 121.0290.

3-Methyl-2-[(2*S*)-(pyrrolidinyl) methylthio]-3*H*-imidazol-1-ium phenylacetate (**1i**)

^1H NMR (DMSO- d_6 , δ ppm) : 1.47-1.54 (m, 1H), 1.66-1.80 (m, 2H), 1.87-1.93 (m, 1H), 2.88-2.99 (m, 2H), 3.15 (dd, $J=14.8$, 20 Hz, 2H), 3.38 (s, 2H), 3.41-3.44 (m, 1H), 3.57 (s, 3H), 6.38 (dr, 2H), 6.93 (s, 1H), 7.17-7.25 (m, 6H).

^{13}C NMR (DMSO- d_6 , δ ppm): 23.871, 29.725, 33.100, 35.724, 44.543, 44.649, 58.336, 123.536, 125.508, 127.836, 128.321, 129.246, 138.346, 139.893, 175.298.

IR (film, cm^{-1}): 3393 [$\nu(\text{N-H})$], 3109 [$\nu(\text{C-H})$ aromatic], 2951 and 2751 [$\nu(\text{C-H})$ aliphatic], 1570 [$\nu(\text{C=O})$], 1458 and 1375 [$\delta(\text{C-H})$], 1411 [$\delta(\text{S-CH}_2)$].

ESI-MS: m/z 198 [$\text{M-C}_6\text{H}_5\text{CH}_2\text{COO}]^+$, 135 [$\text{C}_6\text{H}_5\text{CH}_2\text{COO}]^-$.

HRMS: (ESI+) m/z calcd for [$\text{C}_9\text{H}_{16}\text{N}_3\text{S}]^+$ 198.1059, found 198.1056. (ESI-) m/z calcd for [$\text{C}_8\text{H}_7\text{O}_2$] 135.0441, found 135.0444.

3-Phenyl-2-[(2*S*)-(pyrrolidinyl) methylthio]-3*H*-imidazol-1-ium bromide (**2**)

^1H NMR (DMSO- d_6 , δ ppm) : 1.69-1.76 (m, 1H), 1.84-1.98 (m, 2H), 2.06-2.14 (m, 1H), 3.16-3.26 (m, 2H), 3.39-3.51 (m, 2H), 3.86-3.92 (m, 1H), 7.17 (d, $J=1.6$ Hz, 1H), 7.47-7.53 (m, 3H), 7.55-7.60 (m, 3H), 9.27 (dr, 2H).

^{13}C NMR (DMSO- d_6 , δ ppm): 23.538, 29.42k, 34.503, 44.922, 58.761, 123.339, 125.219, 128.541, 129.064, 129.527, 136.496, 140.515.

IR (film, cm^{-1}): 3427 [$\nu(\text{N-H})$], 3086 [$\nu(\text{C-H})$ aromatic], 2961 and 2722 [$\nu(\text{C-H})$ aliphatic], 1593 and 1498 [$\nu(\text{C=C})$], 1478 and 1344 [$\delta(\text{C-H})$], 1418 [$\delta(\text{S-CH}_2)$], 767 [$\delta(\text{Ar-H})$].

ESI-MS: m/z 260 [$\text{M-Br}]^+$.

HRMS: (ESI+) m/z calcd for [$\text{C}_{14}\text{H}_{18}\text{N}_3\text{S}]^+$ 260.1216, found 260.1221.

3-Benzyl-2-[(2*S*)-(pyrrolidinyl) methylthio]-3*H*-imidazol-1-ium bromide (**3**)

^1H NMR (DMSO- d_6 , δ ppm) : 1.68-1.76 (m, 1H), 1.83-1.98 (m, 2H), 2.06-2.12 (m, 1H), 3.18-3.24 (m, 2H), 3.34 (s, 2H), 3.35-3.49 (m, 2H), 3.87-3.91 (m, 1H), 7.17 (d, $J=1.6$ Hz, 1H), 7.46-7.53 (m, 3H), 7.56-7.60 (m, 1H), 9.20 (dr, 2H).


^{13}C NMR (DMSO- d_6 , δ ppm): 23.629, 29.430, 35.162, 44.990, 49.623, 59.315, 123.164, 127.282, 127.942, 128.784, 128.882, 136.928, 140.158.

IR (film, cm^{-1}): 3388 [$\nu(\text{N-H})$], 3029 [$\nu(\text{C-H})$ aromatic], 2928 and 2708 [$\nu(\text{C-H})$ aliphatic], 1604 and 1496 [$\nu(\text{C=C})$], 1583 [$\nu(\text{C=O})$], 1519 [$\nu(\text{-NO}_2)$], 1454 and 1358 [$\delta(\text{C-H})$], 1430 [$\delta(\text{S-CH}_2)$], 715 [$\delta(\text{Ar-H})$].

ESI-MS: m/z 274 [$\text{M-Br}]^+$.

HRMS: (ESI+) m/z calcd for $[C_{15}H_{20}N_3S]^+$ 274.1372, found 274.1380.

3. Typical Experimental Procedure for the Asymmetric Michael Addition Reaction



To a mixture of nitrostyrene (0.5 mmol) and a chiral pyrrolidinyl-thioimidazolium salt catalyst (0.1 mmol) in PEG-800 (2 mL) was added cyclohexanone (1 mmol). The mixture was stirred at room temperature until completion of the reaction by monitoring on GC. The mixture was extracted four times with hexane/ether (6:1). The combined extracts were evaporated and purified by preparative TLC (hexane/ CHCl_3 = 4:1) to give the Michael adduct. The ee value of the product was determined by chiral HPLC analysis.³

2-(2-Nitro-1-phenylethyl) cyclohexanone (6)

HPLC (Daicel Chiralpak AS-H, hexane/2-PrOH=95:5, flow rate 1.0 mL/min, λ =254nm): t_R =14.28 min (minor), 20.84 min (major).

^1H NMR (CDCl_3 , δ ppm): 1.19-2.72 (m, 9H, cycl), 3.75 (ddd, J =10, 10, 4.8 Hz, 1H), 4.63 (dd, J =12.4, 10 Hz, 1H), 4.95 (dd, J =12.4, 4.8 Hz, 1H), 7.16-7.34 (m, 5H).

MS (EI): 55 (30), 77 (12), 91 (63), 104 (34), 115 (25), 141 (15), 157 (13), 171 (100), 183 (21), 200 (60), 247 (1).

2-(2-Nitro-1-(2-methoxyphenyl) ethyl) cyclohexanone (7)

HPLC (Daicel Chiralpak AS-H, hexane/2-PrOH=90:10, flow rate 1.0 mL/min, λ =254nm): t_R =10.19 min (minor), 18.09 min (major).

^1H NMR (CDCl_3 , δ ppm): 1.16-1.25 (m, 1H), 1.56-1.79 (m, 4H), 2.05-2.09 (m, 1H), 2.35-2.49 (m, 2H), 2.94-3.01 (m, 1H), 3.84 (s, 3H), 3.95 (dt, J =9.2, 4.9 Hz, 1H), 4.80-4.88 (m, 2H), 6.88 (t, J =8.4 Hz, 2H), 7.08 (d, J =7.6 Hz, 1H), 7.24 (dd, J =8.4, 7.6 Hz, 1H).

MS (EI): 55 (11), 77 (17), 91 (15), 105 (11), 121 (60), 134 (54), 145 (10), 159 (12), 171 (9), 187 (7), 201 (100), 213 (6), 230 (51), 277 (10).

2-(2-Nitro-1-(3-methoxyphenyl) ethyl) cyclohexanone (8)

HPLC (Daicel Chiralpak AS-H, hexane/2-PrOH=90:10, flow rate 1.0 mL/min, λ =254nm): t_R =14.16 min (minor), 22.20 min (major).

^1H NMR (CDCl_3 , δ ppm): 1.21-1.27 (m, 1H), 1.55-1.81 (m, 4H), 2.07-2.10 (m, 1H), 2.35-2.49 (m, 2H), 2.62-2.70 (m, 1H), 3.70-3.77 (m, 1H), 3.79 (s, 3H), 4.62 (dd, J =10.4, 12.0 Hz, 1H), 4.92 (dd, J =12.0,

4.0 Hz, 1H), 6.71 (s, 1H), 6.75 (d, $J=8.0$ Hz, 1H), 6.79 (d, $J=8.0$ Hz, 1H), 7.25 (t, $J=8.0$ Hz, 1H).

MS (EI): 55 (5), 77 (16), 91 (26), 103 (14), 121 (39), 134 (27), 147 (11), 159 (18), 171 (10), 187 (14), 201 (100), 213 (33), 230 (38), 277 (19).

2-(2-Nitro-1-(4-methoxyphenyl) ethyl) cyclohexanone (**9**)

HPLC (Daicel Chiralpak AS-H, hexane/2-PrOH=90:10, flow rate 1.0 mL/min, $\lambda=254$ nm): $t_R=14.12$ min (minor), 23.09 min (major).

^1H NMR (CDCl_3 , δ ppm): 1.15-1.27 (m, 1H), 1.64-1.77 (m, 4H), 2.02-2.11 (m, 1H), 2.31-2.50 (m, 2H), 2.60-2.72 (m, 1H), 3.71 (ddd, $J=9.6, 9.6, 4.6$ Hz, 1H), 3.78 (s, 3H), 4.58 (dd, $J=12.4, 9.6$ Hz, 1H), 4.90 (dd, $J=12.4, 4.6$ Hz, 1H), 6.85 (d, $J=6.7$ Hz, 2H), 7.09 (d, $J=6.7$ Hz, 2H).

MS (EI): 55 (4), 77 (6), 91 (14), 103 (5), 121 (39), 134 (74), 147 (6), 176 (5), 187 (7), 201 (100), 213 (6), 230 (54), 277 (3).

2-(2-Nitro-1-(4-methylphenyl) ethyl) cyclohexanone (**10**)

HPLC (Daicel Chiralpak AS-H, hexane/2-PrOH=95:5, flow rate 1.0 mL/min, $\lambda=254$ nm): $t_R=8.79$ min (minor), 13.70 min (major).

^1H NMR (CDCl_3 , δ ppm): 1.18-1.28 (m, 1H), 1.52-1.79 (m, 4H), 2.04-2.10 (m, 1H), 2.33 (s, 3H), 2.35-2.50 (m, 2H), 2.63-2.70 (m, 1H), 3.69-3.75 (ddd, $J=10, 10, 4.8$ Hz, 1H), 4.60 (dd, $J=12, 10$ Hz, 1H), 4.91 (dd, $J=12, 4.8$ Hz, 1H), 7.04 (d, $J=8.4$ Hz, 2H), 7.12 (d, $J=8.4$ Hz, 2H).

MS (EI): 55 (6), 77 (7), 91 (17), 105 (47), 118 (36), 129 (16), 147 (13), 155 (11), 171 (11), 185 (100), 197 (13), 214 (53).

2-(2-Nitro-1-(4-chlorophenyl) ethyl) cyclohexanone (**11**)

HPLC (Daicel Chiralpak AS-H, hexane/2-PrOH=95:5, flow rate 1.0 mL/min, $\lambda=254$ nm): $t_R=11.10$ min (minor), 15.03 min (major).

^1H NMR (CDCl_3 , δ ppm): 1.19-1.30 (m, 1H), 1.61-1.82 (m, 4H), 2.08-2.10 (m, 1H), 2.34-2.50 (m, 2H), 2.63-2.67 (m, 1H), 3.75 (ddd, $J=10, 10, 4.4$ Hz, 1H), 4.61 (dd, $J=12.4, 10$ Hz, 1H), 4.93 (dd, $J=12.4, 4.4$ Hz, 1H), 7.15 (d, $J=8.4$ Hz, 2H), 7.34 (d, $J=8.4$ Hz, 2H).

MS (EI): 55 (13), 77 (10), 89 (7), 103 (16), 115 (23), 125 (57), 138 (37), 151 (11), 165 (12), 175 (7), 182 (8), 191 (13), 205 (100), 217 (14), 234 (50).

2-(2-Nitro-1-(4-trifluoromethylphenyl) ethyl) cyclohexanone (**12**)

HPLC (Daicel Chiralpak AS-H, hexane/2-PrOH=95:5, flow rate 1.0 mL/min, $\lambda=254$ nm): $t_R=8.14$ min (minor), 11.86 min (major).

^1H NMR (CDCl_3 , δ ppm): 1.25-2.70 (m, 9H, cycl), 3.98 (m, 1H), 4.66 (m, 1H), 4.99 (m, 1H), 7.59 (d, $J=8.8$ Hz, 2H), 8.31 (d, $J=8.8$ Hz, 2H).

MS (EI): 55 (30), 69 (12), 81 (8), 103 (8), 115 (15), 129 (17), 151 (14), 159 (68), 173 (35), 185 (24), 199 (16), 209 (15), 225 (19), 239 (100), 251 (34), 268 (53).

2-(2-Nitro-1-(2-nitrophenyl) ethyl) cyclohexanone (**13**)

HPLC (Daicel Chiralpak AD-H, hexane/2-PrOH=90:10, flow rate 1.0 mL/min, λ =254nm): t_R =20.68 min (minor), 24.94 min (major).

^1H NMR (CDCl_3 , δ ppm): 1.24-2.66 (m, 9H, cycl), 4.09-4.13 (m, 1H), 4.30-4.35 (m, 1H), 4.93-4.95 (m, 1H), 7.38-7.47 (m, 2H), 7.54-7.65 (m, 1H), 7.84-7.90 (m, 1H).

MS (EI): 55 (49), 67 (22), 77 (41), 91 (31), 104 (20), 115 (39), 130 (36), 144 (19), 156 (17), 168 (13), 185 (91), 200 (20), 246 (100).

2-(2-Nitro-1-(furan-2-yl) ethyl) cyclohexanone (**14**)

HPLC (Daicel Chiralpak AS-H, hexane/2-PrOH=85:15, flow rate 1.0 mL/min, λ =254nm): t_R =13.01 min (minor), 15.55 min (major).

^1H NMR (CDCl_3 , δ ppm): 1.25-2.79 (m, 9H, cycl), 3.98 (ddd, J =9.6, 9.6, 4.8 Hz, 1H), 4.67 (dd, J =12.4, 9.6 Hz, 1H), 4.80 (dd, J =12.4, 4.8 Hz, 1H), 6.18 (s, 1H), 6.29 (s, 1H), 7.34 (s, 1H).

MS (EI): 55 (11), 65 (9), 77 (14), 81 (29), 91 (15), 94 (33), 108 (10), 121 (9), 134 (9), 147 (14), 161 (100), 190 (63), 237 (1).

2-(2-Nitro-1-(thioan-2-yl) ethyl) cyclohexanone (**15**)

HPLC (Daicel Chiralpak AS-H, hexane/2-PrOH=90:10, flow rate 1.0 mL/min, λ =254nm): t_R =14.52 min (minor), 18.26 min (major).

^1H NMR (CDCl_3 , δ ppm): 1.28-2.79 (m, 9H, cycl), 4.13 (ddd, J =8.8, 8.8, 4.4 Hz, 1H), 4.65 (dd, J =12.0, 8.8 Hz, 1H), 4.89 (dd, J =12.0, 4.4 Hz, 1H), 6.91-6.95 (m, 2H), 7.21-7.23 (m, 1H).

MS (EI): 55 (10), 65 (9), 77 (10), 97 (50), 110 (50), 123 (15), 135 (16), 150 (10), 163 (14), 177 (100), 189 (4), 206 (70).

2-(2-Nitro-1-(2-naphthyl) ethyl) cyclohexanone (**16**)

HPLC (Daicel Chiralpak AS-H, hexane/2-PrOH=85:15, flow rate 1.0 mL/min, λ =254nm): t_R =11.75 min (minor), 20.94 min (major).

^1H NMR (CDCl_3 , δ ppm): 1.19-2.78 (m, 9H, cycl), 3.93 (ddd, J =10, 10, 4.4 Hz, 1H), 4.73 (t, J =12.4 Hz, 1H), 5.01 (dd, J =12.4, 4.4 Hz, 1H), 7.27-7.82 (m, 7H).

MS (EI): 55 (16), 73 (16), 81 (25), 115 (16), 128 (17), 141 (52), 154 (53), 165 (39), 179 (28), 191 (15), 207 (46), 221 (100), 250 (43), 281 (21), 297 (10).

3-(2-Nitro-1-phenylethyl) tetrahydro-pyran-4-one (**17**)

HPLC (Daicel Chiralpak AS-H, hexane/2-PrOH=90:10, flow rate 1.0 mL/min, λ =254nm): t_R =12.90 min (minor), 34.85 min (major).

^1H NMR (CDCl_3 , δ ppm): 2.54-2.59 (m, 1H), 2.64-2.71 (m, 1H), 2.85-2.92 (m, 1H), 3.25-3.30 (m, 1H), 3.60-3.72 (m, 1H), 3.75-3.86 (m, 2H), 4.15 (m, 1H), 4.65 (dd, J =12.4, 10.4 Hz, 1H), 4.93 (dd, J =12.4,

4.8 Hz, 1H), 7.18 (d, $J=7.6$ Hz, 2H), 7.23-7.36 (m, 3H).

MS (EI): 51 (9), 65 (8), 77 (18), 91 (53), 104 (33), 115 (49), 131 (100), 145 (6), 157 (18), 172 (22), 187 (6), 202 (78).


3-(2-Nitro-1-phenyl-ethyl) tetrahydro-thiopyran-4-one (**18**)

HPLC (Daicel Chiralpak AS-H, hexane/2-PrOH=90:10, flow rate 1.0 mL/min, $\lambda=254$ nm): $t_R=25.34$ min (minor), 33.38 min (major).


^1H NMR (CDCl_3 , δ ppm): 2.46 (dd, $J=13.6$, 10 Hz, 1H), 2.60-2.63 (m, 1H), 2.75-2.90 (m, 2H), 2.93-3.09 (m, 3H), 3.95-4.01 (m, 1H), 4.64 (dd, $J=12.4$, 10 Hz, 1H), 4.76 (dd, $J=12.4$, 4.4 Hz, 1H), 7.20 (d, $J=6.8$ Hz, 2H), 7.27-7.41 (m, 3H).

MS (EI): 65 (12), 77 (23), 91 (56), 104 (40), 115 (73), 131 (100), 147 (7), 157 (12), 162 (35), 171 (11), 190 (35), 218 (59), 265 (4).


4. NMR, ESI-MS and HRMS Spectra of Pyrrolidinyl-Thioimidazolium Salts 1-3




1 or 1a





ProMISHBr #20 RT: 0.40 AV: 1 NL: 9.30E6
T: + c ESI Full ms [50.00-800.00]




ProMISHBr #13 RT: 0.22 AV: 1 NL: 2.44E5
T: - c ESI Full ms [50.00-800.00]








1b





T: + c ESI Full ms [50.00-250.00]





WVF-3 # 03 RT: 1.59 AV: NL: 1.18E5


T: + c ESI Full ms [50.00-250.00]















WVF-9 #16 RT: 0.20 AV: 1 NL: 7.0-E9

T: + c ESI ms [60.00-220.00]













WYF-6 #12 RT: 0.16 AV: 1 NL: 1.04E7
T: + c ESI Full ms [50.00-250.00]




WYF-6 #23 RT: 0.31 AV: 1 NL: 1.54E5
T: + c ESI Full ms [50.00-250.00]













WYF-6 #22 RT: 0.23 AV: 1 NL: 4.55E6
T: + c ESI Full ms [50.00-350.00]




WYF-6 #2 RT: 0.02 AV: 1 NL: 1.97E5
T: - c ESI ms [50.00-400.00]













APF-1 #38 RT: 0.47 AV: 1 NL: 3.42E6
T: +c ESI Full ms [50.00-250.00]




APF-1 #38 RT: 0.38 AV: 1 NL: 8.41E5
T: -c ESI Full ms [50.00-250.00]













060925081407 #3 RT: 0.10 AV: 1 NL: 8.05E6
T: -c ESI Full ms [50.00-240.00]






060925081407 #13 RT: 0.16 AV: 1 NL: 5.63E6
T: -c ESI Full ms [50.00-240.00]


































2













ProSBnIBr #1 RT: 0.01 AV: 1 NL: 7.77E8
T: + c ESI Full ms [50.00-800.00]





5. X-Ray Crystal Data and Structure of **1f**'s Hydrobromide Salt

Table 1 Crystal data and structure refinement for **1f**'s hydrobromide salt

Empirical formula	C ₁₆ H ₂₄ Br N ₃ O ₃ S ₂
Formula weight	450.41
Temperature	293 (2) K
Wavelength	0.71073 Å
Crystal system, space group	Orthorhombic, P2 (1) 2 (1) 2 (1)
Unit cell dimensions	a = 7.022 (7) Å alpha = 90 deg. b = 7.332 (8) Å beta = 90 deg. c = 38.75 (4) Å gamma = 90 deg.
Volume	1995 (4) Å ³
Z, Calculated density	4, 1.499 Mg/m ³
Absorption coefficient	2.289 mm ⁻¹
F(000)	928
Crystal size	0.496 x 0.421 x 0.197 mm
Theta range for data collection	2.10 to 26.99 deg.
Limiting indices	-7<=h<=8, -9<=k<=8, -45<=l<=49
Reflections collected / unique	11718 / 4309 [R(int) = 0.1452]
Completeness to theta = 26.99	99.8 %
Absorption correction	Empirical
Max. and min. transmission	1.00000 and 0.56229
Refinement method	Full-matrix least-squares on F ²
Data / restraints / parameters	4309 / 0 / 233
Goodness-of-fit on F ²	0.918
Final R indices [I>2sigma(I)]	R1 = 0.0648, wR2 = 0.1477
R indices (all data)	R1 = 0.0869, wR2 = 0.1581
Absolute structure parameter	-0.004(14)
Extinction coefficient	0.0047(14)
Largest diff. peak and hole	0.935 and -0.760 e.Å ⁻³

For crystallographic data in CIF or other electronic format see <http://dx.doi.org/10.1039/b000000x>. CCDC: 639780





Figure 1 Molecular structure of **1f**'s hydrobromide salt

6. HPLC Chart for ee Value Determination and Crystal Structure of Michael Adduct 6

HPLC Chart of Michael Adduct 6






Table 2 Crystal data and structure refinement for Michael adduct **6**

Empirical formula	C ₁₄ H ₁₇ N O ₃
Formula weight	247.29
Temperature	296 (1) K
Wavelength	0.71069 Å
Crystal system	orthorhombic
Space group	P 2 ₁ 2 ₁ 2 ₁
Unit cell dimensions	<i>a</i> = 5.578 (4) Å <i>b</i> = 8.563 (18) Å <i>c</i> = 27.852 (3) Å
Volume, <i>z</i>	1330(3) Å ³ , 4
Density (calculated)	1.235 Mg/m ³
Absorption coefficient	0.087 mm ⁻¹
<i>F</i> (000)	528.00
Crystal size	0.35 X 0.25 X 0.20 mm
Range for data collection	3.2 to 27.48°
Limiting indices	-7 ≤ <i>h</i> ≤ 6, -10 ≤ <i>k</i> ≤ 11, -36 ≤ <i>l</i> ≤ 36
Reflections collected	10339
Independent reflection	2937 (<i>R</i> _{int} = 0.033)
Absorption corrections	multi-scan
Max. and min. transmission	0.983 and 0.958
Refinement method	Full-matrix least-squares on <i>F</i> ²
Data / restraints / parameters	2937 / 0 / 165
Goodness-of-fit on <i>F</i> ²	1.004
Final <i>R</i> indices [<i>I</i> > 2σ(<i>I</i>)]	<i>R</i> 1 = 0.0369, <i>wR</i> 2 = 0.0671
Largest diff. Peak and hole	0.25 and -0.24 e Å ⁻³
Absolute structure Flack	-0.0006(14)




Figure 2 Molecular structure of Michael adduct **6** and its packing arrangement in unit cell

References:

- (1) Armarego, W. L. F.; Perrin, D. D. *Purification of Laboratory Chemicals*, 4th ed.; Butterworth-Heinemann: Oxford, U. K., 1997.
- (2) (a) Browden, K.; Green, P. N. *J. Chem. Soc.* **1952**, 1164. (b) Ikegami, S.; Uoji, K.; Akaboshi, S. *Tetrahedron* **1974**, 30, 2077.
- (3) Xu, D. Q.; Luo, S. P.; Yue, H. D.; Wang, L. P.; Liu, Y. K.; Xu, Z.Y. *Synlett* **2006**, 2569.